| |
| |
|
| Insider
Information: |
Kayyem Jon Faiz |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
375,074 |
|
|
Indirect Shares
|
10,693,978 |
|
|
| Direct
Value |
$4,750,833 |
|
|
|
Indirect Value
|
$17,161,998 |
|
|
| Total
Shares |
11,069,052 |
|
|
| Total
Value |
$21,912,830 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Aeolus Pharmaceuticals Inc |
AOLS |
10% Owner |
|
0 |
2006-06-05 |
9,800,000 |
Premium* |
|
|
Genmark Diagnostics, Inc. |
GNMK |
SVP, Research & Develo... |
2018-02-02 |
197,622 |
2018-02-02 |
713,893 |
Premium* |
|
|
Inhibrx, Inc. |
INBX |
Director |
2022-08-02 |
0 |
2024-05-30 |
0 |
Premium* |
|
|
Biodesix Inc |
BDSX |
|
2023-08-03 |
177,452 |
2023-08-03 |
180,085 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
91 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2013-10-01 |
4 |
AS |
$12.14 |
$72,840 |
I/I |
(6,000) |
106,934 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
Chief Scientific Officer |
• – – |
2013-04-01 |
4 |
AS |
$12.93 |
$77,580 |
I/I |
(6,000) |
118,934 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2014-07-01 |
4 |
AS |
$13.60 |
$81,600 |
I/I |
(6,000) |
88,934 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2014-03-04 |
4 |
AS |
$12.47 |
$88,453 |
D/D |
(7,095) |
99,060 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2014-01-15 |
4 |
AS |
$14.00 |
$147,266 |
I/I |
(10,519) |
608,789 |
0 |
- |
|
| BDSX |
Biodesix Inc |
|
• • – |
2022-11-21 |
4 |
B |
$1.15 |
$200,000 |
I/I |
173,913 |
173,913 |
0.01 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
Chief Scientific Officer |
• – – |
2012-06-26 |
4 |
B |
$4.20 |
$210,000 |
I/I |
50,000 |
144,960 |
1.99 |
- |
|
| INBX |
Inhibrx, Inc. |
Director |
– • – |
2023-01-23 |
4 |
AS |
$25.26 |
$239,999 |
I/I |
(9,500) |
3,224,301 |
0 |
- |
|
| INBX |
Inhibrx, Inc. |
Director |
– • – |
2022-12-21 |
4 |
AS |
$26.87 |
$256,679 |
I/I |
(9,500) |
3,233,801 |
0 |
- |
|
| INBX |
Inhibrx, Inc. |
Director |
– • – |
2022-11-21 |
4 |
AS |
$29.33 |
$283,972 |
I/I |
(9,500) |
3,243,301 |
0 |
- |
|
| INBX |
Inhibrx, Inc. |
Director |
– • – |
2022-10-21 |
4 |
AS |
$29.39 |
$286,232 |
I/I |
(9,500) |
3,252,801 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
Chief Scientific Officer |
• – – |
2011-06-22 |
4 |
B |
$4.25 |
$425,000 |
I/I |
100,000 |
669,308 |
1.99 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2014-01-16 |
4 |
AS |
$14.06 |
$555,103 |
I/I |
(39,481) |
569,308 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
SVP, Research & Development |
• – – |
2014-01-02 |
4 |
AS |
$13.18 |
$1,397,080 |
I/I |
(106,000) |
619,308 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
President & CEO |
• • – |
2010-06-03 |
4 |
B |
$6.00 |
$1,500,000 |
I/I |
250,000 |
569,308 |
2.66 |
- |
|
| INBX |
Inhibrx, Inc. |
Director |
– • – |
2024-05-30 |
4 |
D |
$30.00 |
$98,229,030 |
I/I |
(3,274,301) |
0 |
0 |
- |
|
91 Records found
|
|
Page 4 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
